Cyted is on a mission to build a world where disease is prevented rather than treated. We focus on providing innovative diagnostic technologies to drive the earlier detection of disease in the gastrointestinal tract, first focused on oesophageal cancer (and its precursor Barrett’s Oesophagus) with a non-endoscopic, minimally-invasive test.
Headquartered in Cambridge, we are at the forefront of developing cutting-edge diagnostic technologies that enable better access to care for patients at risk or early and advanced disease. Leveraging expertise in GI and, biomarker discovery, we are focussed on improving patient outcomes by detecting gastrointestinal cancer and inflammatory disease when it is more easily treated.
Our core product is the minimally invasive EndoSign test. The test is a combination of a simple device coupled with laboratory biomarkers to detect oesophageal cancer and its precursor Barrett’s Oesophagus. The test sees patients swallow a capsule attached to a strong, thin thread. The capsule dissolves in the stomach, releasing the sponge. This is then gently pulled back out, collecting cells from the entire length of the oesophagus. The collection of cells using the EndoSign cell collection device is a simple, minimally invasive procedure that can be carried out within 10 minutes and has significant benefits over the alternative procedures currently offered in healthcare settings. To find out more about the EndoSign test please see HERE.To date, we have tested over 16,000 patients across the UK in over 60 NHS Trusts and 10 community-based clinics in GPs and Community Diagnostic Centres. We process the samples in our fully digital laboratory and leverage AI to optimise reporting of the pathology results